Synthesis and anti‐HIV activity of non‐nucleoside reverse‐transcriptase inhibitor DB02 phosphate derivatives based on water‐soluble optimization

Abstract

AbstractTo improve the water solubility of anti‐human immunodeficiency virus (HIV) agent DB02, an excellent non‐nucleoside reverse‐transcriptase inhibitor (NNRTI) obtained in our previous efforts, we designed and synthesized four phosphate derivatives of DB02 based on the molecular model of DB02 with RT. Here, the antiviral activity of these four derivatives was detected, leading to the discovery of compound P‐2, which possessed a superior potency to the lead compound DB02 against wild‐type HIV‐1 and a variety of HIV‐resistant mutant viruses significantly. Furthermore, the water solubility of P‐2 was nearly 17 times higher than that of DB02, and the pharmacokinetic test in rats showed that P‐2 demonstrate significantly improved oral bioavailablity of 14.6%. Our study showed that the introduction of a phosphate ester group at the end of the C‐2 side chain of DB02 was beneficial to the improvement of its antiviral activity and pharmacokinetic properties, which provided a promising lead for the further development of S‐DACOs type of NNRTIs.